AI Engines For more Details: Perplexity Kagi Labs You
Rank | Probiotic | Impact |
---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
Taxonomy | Rank | Effect | Citations | Notation |
---|---|---|---|---|
Staphylococcus | genus | Decreases | 👪 Source Study | |
Staphylococcus aureus | species | Decreases | 📓 Source Study | Skin infections, sinusitis, food poisoning |
Staphylococcus aureus 04-02981 | strain | Decreases | 👶 Source Study | |
Staphylococcus aureus 07-03450 | strain | Decreases | 👶 Source Study | |
Staphylococcus aureus SK6575 | strain | Decreases | 👶 Source Study | |
Staphylococcus aureus subsp. aureus Mu50 | strain | Decreases | 👶 Source Study | H00330 Methicillin-resistant Staphylococcal aureus (MRSA) infection |
Staphylococcus aureus subsp. aureus MW2 | strain | Decreases | 👶 Source Study | H00330 Methicillin-resistant Staphylococcal aureus (MRSA) infection |
Staphylococcus aureus subsp. aureus N315 | strain | Decreases | 👶 Source Study | H00330 Methicillin-resistant Staphylococcal aureus (MRSA) infection |
Staphylococcus aureus aureus | subspecies | Decreases | 👶 Source Study |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Allergies | 0.5 | -0.5 | |
Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
Asthma | 0.5 | 0.5 | 0 |
Autism | 0.3 | 0.3 | |
Brain Trauma | 0.3 | -0.3 | |
Cancer (General) | 0.3 | -0.3 | |
Celiac Disease | 0.3 | 0.3 | |
Coagulation / Micro clot triggering bacteria | 0.5 | 0.5 | |
deep vein thrombosis | 0.5 | 0.5 | |
Functional constipation / chronic idiopathic constipation | 0.5 | 0.5 | |
Hidradenitis Suppurativa | 0.3 | 0.3 | |
hyperglycemia | 0.3 | 0.3 | |
hypertension (High Blood Pressure | 0.3 | 0.3 | 0 |
Inflammatory Bowel Disease | 0.3 | 0.3 | |
Liver Cirrhosis | 0.8 | 0.3 | 1.67 |
Metabolic Syndrome | 0.3 | 0.3 | 0 |
Obesity | 0.3 | 0.3 | 0 |
obsessive-compulsive disorder | 0.3 | 0.3 | |
Psoriasis | 0.5 | 0.5 | |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.3 | 0.3 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
Stress / posttraumatic stress disorder | 0.3 | 0.3 | |
Type 1 Diabetes | 0.3 | -0.3 | |
Type 2 Diabetes | 0.3 | 0.3 | 0 |
Ulcerative colitis | 0.3 | 0.3 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.